Chronic Myeloid Leukemia

P=N/A, N=30, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed

Our findings demonstrate that benzene metabolites trigger cell pyroptosis via the canonical NLRP3/Caspase-1/GSDMD signaling pathway, which also enhances and enriches the molecular regulatory network of benzene induced hematopoietic toxicity In addition, we found that targeting NLRP3 may provide a promising prevention and treatment strategy for benzene induced hematopoietic injury, and provide potential molecular targets for the development of preventive drugs and early intervention agents for benzene poisoning, which has important research significance.

IGF2BP3 serves as a robust biomarker for disease progression and therapeutic resistance in CML. Elevated IGF2BP3 expression may identify patients at higher risk of poor treatment response and relapse, making it valuable for risk stratification and longitudinal disease monitoring. While this study does not address therapeutic targeting of IGF2BP3, its strong association with resistance phenotypes supports further exploration of IGF2BP3 as a predictive biomarker in precision hematologic oncology.

This case highlights a rare cytogenetic abnormality in CML characterized by acquired pericentric inversion of the derivative chromosome 9 associated with BCR and ABL1 codeletion. Such complex rearrangements likely reflect clonal evolution and may be associated with suboptimal response to first line imatinib therapy. Accurate discrimination between constitutional and acquired inv(9), together with detailed assessment of derivative chromosome 9 integrity, is essential for prognostic stratification. Comprehensive cytogenetic and molecular analyses remain critical for identifying uncommon secondary abnormalities that may influence therapeutic response and clinical outcome in CML.

P=N/A, N=38, Suspended, University of Wisconsin, Madison | Recruiting --> Suspended

P=N/A, N=2000, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2026 --> Jan 2027

Dasatinib de-escalation after 100 mg standard dose achieved superior early response, fewer discontinuations, and sustained outcomes versus upfront low-dose therapy. This first Indian study supports de-escalation as an effective, real-world dose-optimization strategy.

The financial and access challenges explored in this study underscore the importance of accelerating more effective and sustainable health policies in the CML field, which include access to the BCR::ABL-1 test with financial accountability.

P2, N=41, Recruiting, Milton S. Hershey Medical Center | Not yet recruiting --> Recruiting

P2, N=69, Recruiting, Korean Society of Hematology | Not yet recruiting --> Recruiting

P1, N=250, Recruiting, Enliven Therapeutics | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027